# EDGAR Filing Document

**Accession Number:** 0001082554
**File Stem:** 0001104659-25-090207
**Filing Date:** 2025-9
**Character Count:** 9620
**Document Hash:** 00482b8e2f4f43b1d0d4e9891c066582
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-090207.hdr.sgml**: 20250916

**ACCESSION NUMBER**: 0001104659-25-090207

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250912

**FILED AS OF DATE**: 20250916

**DATE AS OF CHANGE**: 20250916

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ROTHBLATT MARTINE A
- **CENTRAL INDEX KEY:** 0001106578

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-26301
- **FILM NUMBER:** 251315850
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UNITED THERAPEUTICS Corp
- **CENTRAL INDEX KEY:** 0001082554
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521984749
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910
- **BUSINESS PHONE:** 3016089292

**MAIL ADDRESS:**
- **STREET 1:** 1000 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** UNITED THERAPEUTICS CORP
- **DATE OF NAME CHANGE:** 19990324

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ROTHBLATT MARTINE A<br><sub>(Last) (First) (Middle)</sub><br>C/O UNITED THERAPEUTICS CORPORATION<br>1000 SPRING STREET<br><sub>(Street)</sub><br>SILVER SPRING, MD 20910<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-09-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chairperson & CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>UNITED THERAPEUTICS Corp [ UTHR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-09-12 |  | M<sup>(1)</sup> |  | 4000 | A | $120.26 | 4130 | D |  |
| Common Stock | 2025-09-12 |  | S<sup>(1)</sup> |  | 1000 | D | 402.21<sup>(2)</sup> | 3130 | D |  |
| Common Stock | 2025-09-12 |  | S<sup>(1)</sup> |  | 1000 | D | 403.91<sup>(3)</sup> | 2130 | D |  |
| Common Stock | 2025-09-12 |  | S<sup>(1)</sup> |  | 2000 | D | 404.89<sup>(4)</sup> | 130 | D |  |
| Common Stock | 2025-09-15 |  | M<sup>(1)</sup> |  | 4000 | A | $120.26 | 4130 | D |  |
| Common Stock | 2025-09-15 |  | S<sup>(1)</sup> |  | 2540 | D | 397.7086<sup>(5)</sup> | 1590 | D |  |
| Common Stock | 2025-09-15 |  | S<sup>(1)</sup> |  | 1460 | D | 398.1889<sup>(6)</sup> | 130 | D |  |
| Common Stock |  |  |  |  |  |  |  | 166 | I | by Spouse |
| Common Stock |  |  |  |  |  |  |  | 324518 | I | by Trust<sup>(7)</sup> |
| Common Stock |  |  |  |  |  |  |  | 258117 | I | by Trust<sup>(8)</sup> |
| Common Stock |  |  |  |  |  |  |  | 45596 | I | by Trust<sup>(9)</sup> |
| Common Stock |  |  |  |  |  |  |  | 15962 | I | by Trust<sup>(10)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | $120.26 | 2025-09-12 |  | M<sup>(1)</sup> |  |  | 4000 | 2016-03-15 | 2026-03-15 | Common Stock | 4000 | $0.00 | 274000 | D |  |
| Stock Option | $120.26 | 2025-09-15 |  | M<sup>(1)</sup> |  |  | 4000 | 2016-03-15 | 2026-03-15 | Common Stock | 4000 | $0.00 | 270000 | D |  |

---

### Footnotes:

(1) This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. Thisplan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025.

(2) This transaction was executed in multiple trades at prices ranging from $402.21 to $403.2099. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected.

(3) This transaction was executed in multiple trades at prices ranging from $403.405 to $404.4049. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected.

(4) This transaction was executed in multiple trades at prices ranging from $404.62 to $405.15. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected.

(5) This transaction was executed in multiple trades at prices ranging from $396.97 to $397.9699. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected.

(6) This transaction was executed in multiple trades at prices ranging from $397.98 to $398.285. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected.

(7) Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members arebeneficiaries.

(8) Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power torevoke.

(9) Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate familymembers are beneficiaries.

(10) Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

**Signature:** /s/ John S. Hess, Jr. under Power of Attorney  
**Date:** 2025-09-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**